- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07479641
Une étude de bioéquivalence de deux formulations de comprimés HRS-1893 chez des participants en bonne santé
This study will investigate the bioequivalence between two formulations of HRS-1893 tablets. Safety and tolerability will also be assessed.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chine, 100730
- Beijing Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Subjects aged 18 to 55 years (inclusive), regardless of gender;
- Body mass index (BMI) between 19 and 28 kg/m² (inclusive), with body weight ≥ 50.0 kg and < 90.0 kg for men, and ≥ 45.0 kg and < 90.0 kg for women;
- No abnormalities of clinical significance are found upon comprehensive physical examination and laboratory tests, or only minor abnormalities that are deemed by the investigator not to affect the subject's eligibility for enrollment;
- No clinically significant abnormalities on the 12-lead ECG;
- The subject must understand the study procedures and methods, voluntarily agree to participate, and provide written informed consent.
Exclusion Criteria:
- Subjects with suspected hypersensitivity to the investigational drug or any excipient;
- The subject has a history of syncope;
- Exclusion due to blood pressure: Systolic Blood Pressure (SBP) >140 mmHg or <90 mmHg; OR Diastolic Blood Pressure (DBP) >90 mmHg or <60 mmHg, as determined by the investigator to be clinically significant;
- History of gastric or intestinal surgery that, in the investigator's judgment, may affect drug absorption;
- A positive result in any one of the following infectious disease screening tests during the screening period: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), treponema pallidum antibody (syphilis), or human immunodeficiency virus antibody/antigen (HIV-Ab/Ag);
- Subjects who meet any of the following criteria will be excluded: a. Smoking: Average daily cigarette consumption of more than 5 cigarettes within the 4 weeks prior to screening; b. Alcohol: Average daily alcohol intake exceeding 15 g within one week prior to screening (15 g of alcohol is equivalent to 450 mL of beer, 150 mL of wine, or 50 mL of low-alcohol spirits); c. Non-compliance: Inability or unwillingness to abstain from smoking, alcohol, and caffeine-containing foods or beverages during the screening period and the entire study duration; d. Diet: Have special dietary requirements, cannot comply with the standardized diet provided in the study, or have a history of substance abuse;
- History of substance abuse;
- Use of any prescription drugs, over-the-counter medications, or Chinese herbal medicines within 1 month prior to dosing, or the use of any drug within 5 half-lives prior to screening (whichever is longer). Additionally, subjects who plan to take any non-study medications during the trial period will be excluded;
- Any other circumstances that, in the investigator's judgment, make the subject unsuitable for participation in the trial. This includes physiological or psychological conditions that may increase the trial risk, affect the subject's protocol compliance, or impact the subject's ability to complete the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Groupe de formulation de test HRS-1893
|
Test formulation of HRS-1893 tablet, oral. |
|
Expérimental: groupe de formulation de référence HRS-1893
|
Reference formulation of HRS-1893 tablet, oral. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Peak concentration (Cmax).
Délai: From Day 1 to Day 17.
|
Primary Pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects. |
From Day 1 to Day 17.
|
|
Area under the plasma concentration - time curve from Time 0 to the last quantifiable time point (AUC0-t).
Délai: From Day 1 to Day 17.
|
Primary Pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects. |
From Day 1 to Day 17.
|
|
Area under the plasma concentration - time curve from Time 0 to infinity (AUC0-∞).
Délai: From Day 1 to Day 17.
|
Primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects. |
From Day 1 to Day 17.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to peak concentration (Tmax).
Délai: From Day 1 to Day 17.
|
Other primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects. |
From Day 1 to Day 17.
|
|
Elimination half-life (t1/2).
Délai: From Day 1 to Day 17.
|
Other primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects. |
From Day 1 to Day 17.
|
|
Apparent clearance (CL/F).
Délai: From Day 1 to Day 17.
|
Other primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects. |
From Day 1 to Day 17.
|
|
Apparent volume of distribution (Vz/F).
Délai: From Day 1 to Day 17.
|
Other primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects. |
From Day 1 to Day 17.
|
|
Incidence and severity of any adverse events (AEs).
Délai: From Day 1 to Day 21 ± 2.
|
Safety and tolerability of different HRS-1893 formulations in healthy subjects. |
From Day 1 to Day 21 ± 2.
|
|
12-Lead Electrocardiogram (ECG) QT Interval.
Délai: From Day 1 to Day 21 ± 2.
|
Safety and tolerability of different HRS-1893 formulations in healthy subjects. |
From Day 1 to Day 21 ± 2.
|
|
Transthoracic echocardiogram (TTE) results.
Délai: From Day 1 to Day 21 ± 2.
|
Safety and tolerability of different HRS-1893 formulations in healthy subjects. |
From Day 1 to Day 21 ± 2.
|
|
Vital signs results - blood pressure.
Délai: From Day 1 to Day 21 ± 2.
|
Safety and tolerability of different HRS-1893 formulations in healthy subjects. |
From Day 1 to Day 21 ± 2.
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- HRS-1893-108
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .